Staphylococcemia
Conditions
Interventions
Research group:Cefbiroxime sodium for Injection, Specification: 500 mg, Manufacturer: Nipro Pharma Corporation-Odate Plant. 500mg was intravenously infused every 2 hours every 8 hours, and the investi
Sponsors
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (SRRSH)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following enrollment criteria to enter this trial. 1. Age >= 18 years; 2. Meet clinical and laboratory diagnostic criteria for Staphylococcus aureus bacteremia (SAB) or methicillin-resistant Staphylococcus aureus (MRSA) infection; 3. Voluntary participation in this study and signed informed consent. If the subject is unable to read the informed consent form (e.g. illiterate subject), witnesses are required to witness the informed process and sign informed consent.
Exclusion criteria
Exclusion criteria: Subjects shall be excluded from this study if they meet any of the following criteria. 1. Definite bloodstream or non-bloodstream concomitant infection with a gram-negative resistant organism that is not susceptible to the test drug; 2. Patients with SAB who have been treated with potentially effective (anti-staphylococcal) systemic antimicrobial therapy for more than 48 h (with the exception of poor efficacy) in the 7 days prior to enrollment, with the exception of clearly documented bloodstream clearance failures; 3. Vulnerable groups, including those with mental illness, cognitive impairment, critically ill patients, and pregnant women. 4. Those deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical cure rate (7-14 days after last treatment or before discharge);Microbial eradication rate (HAP CAP or SAB 7-14 or 70 days after the last treatment, and before discharge, respectively);Early clinical response (3 or 4 days after first treatment);Clinical failure rate (7-14 days after last treatment or before discharge); | — |
Countries
China
Contacts
Public ContactYu Yunsong/Du Xiaoxing
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (SRRSH)
Outcome results
None listed